Published Optimization of IV Ketamine for Treatment Resistant Depression (NYC)

nuke

Bluelighter
Joined
Nov 7, 2004
Messages
4,191
Optimization of IV Ketamine for Treatment Resistant Depression

Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a high-affinity N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, has been used as a standard intravenous (IV) anesthetic agent for many years in both pediatric and adult patients. Beyond its well-established role in anesthesia and pain management, there is emerging evidence that ketamine may have rapid antidepressant properties for patients with severe mood disorders.

In this study we are investigating whether ketamine can have an antidepressant effect compared to midazolam. Midazolam has similar anesthetic effects compared to ketamine but has not been shown to be an antidepressant, and is therefore acting as an active control in this study.

The study period will last up to 6 weeks, depending on your response to the study medication. There are two required overnight stays in our General Clinical Research Center as part of this study.

Estimated Enrollment: 64
Study Start Date: November 2008
Estimated Study Completion Date: November 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)

Contacts
Contact: Jazmin Moral, MSW 212-241-0449 [email protected]
Contact: Heidi Fitterling 212-241-7906

Locations
United States, New York
Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10029
Principal Investigator: Sanjay J Mathew, MD
 
Last edited by a moderator:
Top